CDC_Test_ID	Test_Case_ [ООВ	Gender	Observatio	Observatio Observatio Observatio
2015 US 2001	Encephalop athy within 7 days of DTaP. Further pertussis is contraindic	02/02/2004		005	Severe allergic reaction after previous dose of
2016-UC-0001	ated.	02/02/2001	F	086	Pertussis Adverse
	Anaphylaxis to previous				reaction to vaccine
2016-UC-0002		10/10/2010	F	080	component Encephalop athy not attributable to another identifiable cause within 7 days of administrati on of a previous
	Encephalop athy within 7 days of				dose of Tdap, DTP, or DTaP
2016-UC-0003	Pediarix.	02/02/2011	F	079	vaccine
2016-UC-0004	Anaphylaxis to previous dose of Pediarix	10/10/2010	F	080	Adverse reaction to vaccine component
	Anaphylaxis to previous dose of				Adverse reaction to vaccine
2016-UC-0005	Anaphylaxis following	06/06/2010	F	080	component severe allergic reaction after previous
2016-UC-0006	previous dose	07/04/2013	F	085	dose of Influenza

2016-UC-0007	Anaphylaxis to previous dose of Hep B. No further	03/03/2003 F	096	severe allergic reaction after previous dose of Hepatitis A severe allergic reaction after previous dose of
2016-UC-0008	o Torecast.	09/09/2006 F	097	Hepatitis B
2016-UC-0009	Anaphylaxis to previous dose of Pentacel	06/06/2010 F	080	Adverse reaction to vaccine component severe allergic reaction
2016-UC-0010	Anaphylaxis to previous dose	05/19/2000 F	090	after previous dose of HPV Severe allergic reaction after
2016-UC-0011	Anaphylaxis to previous dose of MCV	02/26/2000 F	095	previous dose of Meningoco ccal
2016-UC-0012	Anaphylacti c reaction to dose 1 of MMR. No forecast for additional dose.	08/13/2010 F	091	Severe allergic reaction after previous dose of Measles
2016-UC-0013	Diagnosis of severe immunodef iciency. No forecast for MMR.	09/10/2011 F	154	HIV/AIDS - severely immunoco mpromised

	. No	17 F 0		allergic reaction after previous dose of Pneumococ cal		
				severe allergic reaction		Severe
to pre	hylaxis evious			after previous		allergic reaction to
dose. 2016-UC-0015 foreca Sever	ast. 07/24/201	1 F 0		dose of Polio	108	streptomyci n
comb				Severe		
icienc				Combined		
(SCID				Immunodef		
rotav 2016-UC-0016 vaccir		2		iciency [SCID]		
2010-0C-0010 Vaccii	02/01/201	.2 F		Severe		
				allergic		
Anan	hylaxis			reaction after		
follov				previous		
previo	_			dose of		
2016-UC-0017 dose	02/01/201	2 F 0		Rotavirus Severe		
				allergic		
Anan	hylaxis			reaction after		
follow				previous		
previo	_			dose of		
2016-UC-0018 dose	02/01/201	2 F 0)83	Rotavirus		
Histor				Healthcare		
VZ=se				provider verified		
comp or exe				history of		
by hx				or diagnosis		
2016-UC-0019 diseas		04 F 0		of Varicella		
Titer				Healthcare		
immu	inity			provider		
to VZ=se	ories			verified history of		
vz–se comp				or diagnosis		
2016-UC-0020 or exe		5 F 0		of Varicella		

Anaphylacti c reaction to dose 1 of 2016-UC-0021 VZ Diagnosis of severe immunodef iciency. No second 2016-UC-0022 dose.	12/12/2010 F 12/12/2009 F	089 154	severe allergic reaction after previous dose of Varicella HIV/AIDS - severely immunoco mpromised
Diagnosis of severe immunodef iciency before administrati on of any VZ. No VZ 2016-UC-0023 to be given.	11/18/2010 F	154	HIV/AIDS - severely immunoco mpromised
Varicella: Patient has laboratory evidence of immunity 2016-UC-0024 for Varicella	06/16/1990 F	023	Laboratory Evidence of Immunity or confirmatio n of Varicella disease
Varicella: Patient has a Varicella verifiable diagnosis by a healthcare 2016-UC-0025 provider.	06/16/1983 F	024	Healthcare provider verified history of or diagnosis of Varicella
Varicella: Patient has a Herpes Zoster verifiable diagnosis by a healthcare 2016-UC-0026 provider.	06/19/1972 F	024	Healthcare provider verified history of or diagnosis of Varicella

2016-UC-0030	Zoster: Anaphylacti c reaction to Zoster vaccine component s (Gelatin or	06/12/1955 F	007	Severe allergic reaction after previous dose of	Severe allergic reaction to
2016-UC-0029	Zoster: Patient is 60 years of age and	06/19/1977 F	007	Pregnant	
2016-UC-0028	Varicella: Patient is a healthcare worker with evidence of immunity for Varicella. Varicella: Patient is	05/20/1968 M	055	Health care personnel	
2016-UC-0027	Varicella: Patient is a healthcare worker without evidence of immunity for Varicella.	03/28/1968 F	055	Health care personnel	

100

Zoster

107

neomycin

2016-UC-0031 neomycin). 06/16/1955 F

2016-UC-0032	MMR: Patient is a healthcare worker, born before 1957, has received one dose of the MMR vaccine.	08/12/1955 F	055	Health care personnel
	Patient is 31 years of age, vaccine naive, and seeking protection			Patient seeks
2016-UC-0033		04/01/1985 M	001	protection
2016-UC-0034	risk 2 dose	05/27/1978 M	001	seeks protection
	Patient is an adult seeking protection from Hepatitis A, and has received the first and second dose of the Hep A risk 2-			Patient seeks
2016-UC-0035	duse selles.	03/17/1991 F	001	protection

2016-UC-0036	Patient is 55 years of age, has chronic liver disease, and has not received Hepatitis A vaccine.	04/12/1961 F	015	Chronic liver disease
2016 UC 0027	Patient has Chronic liver disease and has received the first dose of the Hep A risk Twinrix 3 dose series	04/12/1051 5	015	Chronic liver
2016-UC-0037	· .	04/12/1961 F	015	disease
2016-UC-0038	Patient has Chronic liver disease and has received the first and second dose of the Hep A risk Twinrix 3 dose series 3.	02/15/1967 M	015	Chronic liver disease
2016-UC-0039	Patient has Chronic liver disease and has received all three doses of the Hep A risk Twinrix 3 dose series	07/25/1966 M	015	Chronic liver disease

2016-UC-004C	Patient is 26 years of age, a Public safety worker exposed to blood or infectious body fluids and has not received the Hepatitis A	01/12/1990 M	057	Public safety worker exposed to blood or infection body fluids
2016-UC-0041	Patient is a Public safety worker exposed to blood or infectious body fluids and has received the first dose of the Twinrix 4 dose series.	01/12/1990 M	057	Public safety worker exposed to blood or infection body fluids
2016-UC-0042	Patient is a Public safety worker exposed to blood or infectious body fluids and has received the first and second dose of the Twinrix 4 dose series.	03/29/1983 M	057	Public safety worker exposed to blood or infection body fluids

Patient is a Public safety worker exposed to blood or infectious body fluids, and has received Public safety the first, second, and worker third doses exposed to of the blood or Twinrix 4 infection 2016-UC-0043 dose series. 03/29/1983 M 057 body fluids Patient is a Public safety worker exposed to blood or infectious body fluids Public and has safety received all worker four doses exposed to of the blood or Twinrix 4 infection 2016-UC-0044 dose series. 06/23/1990 F 057 body fluids Patient is 50 years of age unvaccinate

01/17/1966 M

End stage

renal

114

disease

d and has

End Stage Renal

2016-UC-0045 disease.

Patient has
End Stage
Renal
disease,
and has
received
the first
dose of the
Hep B risk
Recombivax
3 dose

series renal 2016-UC-0046 vaccine. 01/17/1966 M 114 disease

End stage

End stage

End stage

Patient has End Stage Renal disease and has

received the first and second dose of the Hep B risk

Recombivax 3 dose

series renal 2016-UC-0047 vaccine. 01/17/1966 M 114 disease

Patient has
End Stage
Renal
disease,
and has
received all
three doses
of the Hep
B risk

Recombivax 3 dose

 series
 renal

 2016-UC-0048 vaccine.
 04/30/1953 F
 114
 disease

69 y age, unv d, a	accinate nd has Stage al	02/13/1947 F	114	End stage renal disease
End Ren dise has rece the dose Hep	eived first e of the B risk erix- B 4-	02/13/1947 F	114	End stage renal disease
End Ren dise and rece the and dose Hep	ase, has eived first second e of the B risk erix- B 4-	02/13/1947 F	114	End stage renal disease
End Ren dise and rece the seco thir of tl B ris	ase, has eived first, ond, and d doses ne Hep sk erix- B 4-	02/13/1947 F	114	End stage renal disease

Patient has End Stage Renal disease and has received all four doses of the Hep B risk Engerix- B 4-			End stage renal
2016-UC-0053 dose series. Patient is a	02/13/1947 F	114	disease
child age 2 years of age, has anatomical or			
functional asplenia, and has not			
received any prior doses of the Hib			Anatomical or functional
2016-UC-0054 vaccine.	07/15/2014 F	160	asplenia
Patient is a child age 2 years of age and has anatomical or functional asplenia and has received the first			Anatomical
dose of the Hib Risk 2			or functional
2016-UC-0055 dose series.	07/15/2014 F	160	asplenia

Patient is a child 2 years of age and has anatomical or functional asplenia and has received the first and second dose of the Hib Risk 2 2016-UC-0056 dose series. Patient is a child 18 months of age, has Persistent complemen t, properdin, or factor B deficiency and has received	07/15/2014 F	160	Anatomical or functional asplenia
only one dose of the Hib vaccine before 12 months of 2016-UC-0057 age.	08/10/2014 F	151	Persistent complemen t, properdin, or factor B deficiency

	Patient is a child that has Persistent complemen t, properdin, or factor B deficiency and has received one dose of the Hib standard vaccine before 12 months of age, and one dose of the Hib risk child 2 dose			Persistent complemen t, properdin, or factor B
2016-UC-0058 2016-UC-0059	Patient is a child that has Persistent complemen t, properdin, or factor B deficiency and has received one dose of the Hib standard vaccine before 12 months of age, and two doses of the Hib risk child 2	08/10/2014 F	151	Persistent complemen t, properdin, or factor B deficiency

2016-UC-0060	child is 36 months of age, has anatomical or functional asplenia and has received two previous doses of the Standard Hib vaccine before 12 months of age and a	04/22/2013 M	160	Anatomical or functional asplenia
2016-UC-0061	dose of the Hib risk child 2 dose series vaccine.	04/22/2013 M	160	Anatomical or functional asplenia

Patient is a

2016-UC-0062	child that is 7 years of age, has not received any Hib vaccine, and is undergoing elective splenectom y.	06/22/2009 M	002	Undergoing elective splenectom y
2016-UC-0063	Patient is a child that is undergoing elective splenectom y and has received the one dose Hib risk 1 dose series	06/22/2009 M	002	Undergoing elective splenectom
2016-UC-0064	Patient is 19 years of age is undergoing elective splenectom y and has no history of receiving Hib vaccine	07/10/1997 F	002	Undergoing elective splenectom y
2016-UC-0065	Patient is 19 years of age and undergoing elective splenectom y and has received the Hib risk 1 dose series	07/10/1997 F	002	Undergoing elective splenectom y

Patient is 12 years of age, has HIV infection, and unvaccinate d with Hib			HIV/AIDS - not severely immunoco
2016-UC-0066 vaccine 12 years of age, has HIV infection,	04/23/2003 F	155	mpromised
and has received the Hib risk 1 dose	04/22/2002 5	155	HIV/AIDS - not severely immunoco
Patient is 4 years of age, a recipient of a successful hematopoi etic stem cell	04/23/2003 F	133	Recipient of a hematopoi etic stem cell
Patient is a child that is a recipient of a successful hematopoi etic stem cell transplant	08/14/2010 M	004	transplant
and has received the first dose of the Hib risk 3- 2016-UC-0069 dose series.	08/14/2010 M	004	Recipient of a hematopoi etic stem cell transplant

	Patient is a child is a recipient of a successful hematopoi etic stem cell transplant and has received the first and second dose of the Hib risk 3-dose series.	04/09/2006	M	004	Recipient of a hematopoi etic stem cell transplant
	Patient is a child is a recipient of a successful hematopoi etic stem cell transplant, and has received all three doses of the Hib risk 3 dose series 6 to 12 months post				Recipient of a hematopoi etic stem cell
2016-UC-0071 2016-UC-0072	Patient is 20 years of age and is a recipient of a successful hematopoi etic stem cell transplant and has not receive recommen ded doses of the HIB	05/28/2004 I		004	Recipient of a hematopoi etic stem cell transplant

6 r 6 0 t 1 6	Patient is an adult recipient of a successful nematopoi etic stem cell cransplant, and has received the first dose of the Hib Risk 3 dose series.	05/13/1996 M	004	Recipient of a hematopoi etic stem cell transplant
	Patient is a adult recipient of a successful nematopoi etic stem cell cransplant, and has received the first and second dose of the Hib Risk 3 dose series.	05/13/1996 M	004	Recipient of a hematopoi etic stem cell transplant
6 6 6 7 1	Patient is a adult recipient of a successful nematopoi etic stem cell cransplant, and has received all three doses of the Hib			Recipient of a hematopoi etic stem

cell transplant

004

Risk 3 dose

05/13/1996 M

2016-UC-0075 series.

2016-UC-0076	Patient is 9 years of age, female, has a history of sexual abuse/assa ult and has not received the HPV vaccine.	04/04/2007 F	169	History of sexual abuse or assault
2016-UC-0077	Patient is a 9 years of age, female, has a history of sexual abuse/assa ult, and has received the first dose of the HPV risk female 2 dose series	04/04/2007 F	169	History of sexual abuse or assault
	Patient is 11 years of age, female, has a history of sexual abuse/assa ult, and has received two doses of the HPV risk female 2 dose			History of sexual abuse or

03/03/2005 F

169

assault

2016-UC-0079 series

2016-UC-0080	Patient is 13 years of age, male, has a history of sexual abuse/assa ult, and has received the first dose of the HPV risk	02/15/2007 M	169	History of sexual abuse or assault History of sexual
2016-UC-0081	male 2 dose series	05/10/2003 M	169	abuse or assault
2016-UC-0083	Patient is 10 years of age, male, has a history of T- Lymphocyt e, and has received three doses of the HPV risk male 3 dose series vaccine. raucine is an adult male, MSM, and has no previous history of	03/13/2006 M	148	T- lymphocyte [cell- mediated and humoral] - Partial defects
2016-UC-0085	the HPV vaccine.	02/02/1994 M	036	have sex with men

Patient is an adult male, MSM, and has received his first dose of the HPV risk adult

risk adult Men who male 3 have sex

2016-UC-0086 dose series. 02/02/1994 M 036 with men

Patient is an adult male, MSM, and has received the first and second dose of the HPV risk adult male

3 dose have sex 2016-UC-0087 series. 01/23/1988 M 036 with men

Men who

Patient is an adult male, MSM, and has received all three doses of the HPV risk adult

risk adult Men who male 3- have sex 2016-UC-0088 dose series. 03/01/1990 M 036 with men

Patient is 32 years of age and plans on traveling to an endemic area (for longer than a month) with Japanese encephalitis

Travelers who plan to spend a month or longer in endemic areas during the JE virus transmissio

2016-UC-0089 . 07/01/1984 F 165

n season

Patient is an adult traveling to an endemic area with Japanese Encephalitis for longer than a month, and

has received the first dose of the Japanese Encephalitis risk 2 dose series

2016-UC-0090 vaccine.

07/01/1984 F

165

who plan to spend a month or longer in endemic areas during the JE virus transmissio n season

Travelers

an adult traveling to an endemic area with Japanese Encephalitis for longer than a month, and has received the first and second dose of the

Japanese

Encephalitis

risk 2 dose

series

Patient is

spend a month or longer in endemic areas during the JE virus transmissio

2016-UC-0091 vaccine.

09/10/1983 M

165

n season

Travelers

who plan to

Patient is 6

months of age and plans to travel with parent from the U.S. for internation al travel and has not received the

Measles

Travelling Internation

(MMR) 2016-UC-0092 vaccine.

02/28/2016 F

048

ally

months of age and is traveling with parents from the U.S. for internation al travel and has received the Measles (MMR) risk 1-dose vaccine

2016-UC-0093 series.

Patient is an adult with perinatal HIV infection who does not have evidence of severe immunosup pression and who was vaccinated with MMR

establishme nt of

05/12/1996 F

2016-UC-0094 antiviral

02/28/2016 F 048 ally Persons with perinatal HIV infection who do not have evidence of severe immunosup pression and who were vaccinated with MMR before before establishme

Travelling

nt of

026

antiviral

therapy

Internation

an adult with perinatal HIV infection

who does not have evidence of severe immunosup pression and who was

vaccinated with MMR before establishme nt of

therapy who has received his first dose of the

antiviral

Measles risk 2 dose 2016-UC-0095 vaccine.

05/12/1996 F

026

Persons
with
perinatal
HIV
infection
who do not
have
evidence of

evidence of severe immunosup pression and who were vaccinated with MMR before establishme nt of antiviral

therapy [ART]

an ad with	lult			
perin	atal			
HIV				
infect	tion			
who o	does			
not h				
evide	nce of			Persons
sever				with
	ınosup			perinatal
press				HIV
and v	vho			infection
was				who do not
vacciı with I				have evidence of
befor				severe
	llishme			immunosup
nt of	MISTITIC .			pression
antivi	iral			and who
thera				were
who l				vaccinated
recei	ved his			with MMR
first a	and			before
secor	nd			establishme
dose	of the			nt of
Meas	les			antiviral
risk 2				therapy
2016-UC-0096 vaccii	111.12	F	026	[ART]
	ears of			
age a				
seeki	_			
prote again				
strain				Patient
Men				seeks
2016-UC-0097 disea		М	001	protection
Patie				•
seekii				
prote	-			
again				
strain	ns of			
Men	В			
disea	se and			
has				
receiv				
the fi				
	of the			
	B risk			Patient
2- do:			001	seeks
2016-UC-0098 series	s. 07/04/1998	M	001	protection

Patient is

	Patient is seeking protection against strains of Men B disease and has received the first and second dose of the Men B risk 2- dose			Patient seeks
: : : : :	Patient is 10 years of age, has anatomical or functional asplenia and has not received	07/04/1998 M	001	protection Anatomical
!	the Meningoco ccal B	02/20/2006 M	100	or functional
	10 years of age, has anatomical or functional asplenia, and has received the first	03/28/2006 M	160	asplenia
 	dose of the Men B risk 2-dose			Anatomical or functional
2016-UC-0101 Y	vaccine.	03/28/2006 M	160	asplenia

2016-UC-0102	Patient is 10 years of age, has anatomical or functional asplenia, and has received the first and second dose of the Men B risk 2-dose vaccine.	03/28/2006 M	160	Anatomical or functional asplenia
	Patient is a microbiolog ist routinely exposed to Neisseria Meningitidi			Microbiolog ists routinely exposed to Neisseria meningitidi
2016-UC-0103		10/01/1976 F	050	S
	Patient is a microbiolog ist routinely exposed to Neisseria Meningitidi s and has received the first dose of the Men B risk			Microbiolog ists routinely exposed to Neisseria
2016-UC-0104	3 dose series	10/01/1976 F	050	meningitidi s
	Patient is a microbiolog ist routinely exposed to Neisseria Meningitidi s and has received the first and second dose of the Men B risk 3 dose			Microbiolog ists routinely exposed to Neisseria meningitidi
2016-UC-0105	series	10/01/1976 F	050	S

	Patient is a microbiolog ist routinely exposed to Neisseria Meningitidi s and has received the first, second, and third dose of the Men B risk 3			Microbiolog ists routinely exposed to Neisseria meningitidi
2016-UC-0106		10/01/1976 F	050	S
	anatomical or			Anatomical or
	functional			functional
2016-UC-0107	' asplenia.	02/14/2015 M	160	asplenia
	Patient is a 2 month old infant with functional asplenia and has received the first dose of the Meningoco ccal ACWY risk start before 7 months			Anatomical or functional
2016-UC-0108		02/14/2015 M	160	asplenia

Patient is a 4 month old infant with functional asplenia and has received the first and second dose of the Meningoco ccal ACWY

risk start before 7

or

Anatomical

Anatomical

or

months functional

asplenia 2016-UC-0109 series. 02/14/2015 M 160

> Patient is a 6 month old infant with functional asplenia and has receive the first,

second, and third dose of the Meningoco

ccal ACWY risk start

before 7

months 4functional 2016-UC-0110 dose series. 02/14/2015 M 160 asplenia

Patient is an 12 month old infant with functional asplenia and has received the first, second, third, and fourth dose of the Meningoco ccal ACWY risk start Anatomical before 7 or months functional 2016-UC-0111 series. 02/14/2015 M 160 asplenia Patient is a 4 year old child who has functional asplenia, has completed the primary doses, and has received the first Anatomical booster or dose at 3 functional 2016-UC-0112 years later. 08/23/2012 M 160 asplenia

Patient is a 9 year old child who has functional asplenia and has received the 3 year booster dose as well as the 5 year booster dose of the Meningoco ccal ACWY

risk start Anatomical

before 7

months functional

2016-UC-0113 series. 01/01/2007 M 160 asplenia

Patient is a 7 month old infant (with no previous history of Meningoco ccal

vaccine) who is at risk for Meningoco

ccal diseasePersons atduring arisk duringcommunityan

2016-UC-0114 outbreak. 05/10/2015 F 070 outbreak

Patient is a 7 month old infant and is at risk during community outbreak of Meningoco ccal disease and has received the first dose of the Meningoco ccal ACWY risk start after 7 months 2 dose

Persons at risk during an

2016-UC-0115 vaccine.

05/10/2015 F

070

outbreak

9 month old infant that was at risk during a community outbreak of Meningoco ccal disease and has received the first dose and second

dose of the Meningoco ccal ACWY risk start after 7 months 2 dose

vaccine but

is no longer

Patient is a

Persons at risk during an

outbreak

2016-UC-0116 at risk

05/10/2015 F

070

months of age, has persistent complemen t deficiencies , and has not received any Meningoco			Persistent complemen t, properdin, or factor B
ccal 2016-UC-0117 vaccine. Patient is 2 months of age, has persistent complemen t deficiencies , and has received	07/28/2015 M	151	or factor B deficiency
the first dose of the Hib MenCY- TT 4-dose series	07/00/0045. A4	454	Persistent complemen t, properdin, or factor B
Patient is 4 months of age and has persistent complemen t deficiencies , and has received the first	07/28/2015 M	151	deficiency
and second dose of the Hib MenCY- TT 4-dose series 2016-UC-0119 vaccine	07/28/2015 M	151	Persistent complemen t, properdin, or factor B deficiency

	Patient is 6 months of age who has persistent complemen t deficiencies , and has received the first, second, and third dose of the Hib MenCY-TT 4-dose series			Persistent complemen t, properdin, or factor B
	vaccine Patient is 11 months of age and has persistent complemen t deficiencies , and has received the first, second, third, and	07/28/2015 M	151	deficiency
	fourth dose of the Hib MenCY-TT 4-dose series	07/28/2015 M	151	Persistent complemen t, properdin, or factor B deficiency

2016 UC 0122	Patient is a child who has persistent complemen t deficiencies , has received the complete Hib MenCy-TT 4 dose series and has received the 3 year booster	11/15/2015 5	151	Persistent complemen t, properdin, or factor B
2016-UC-0122	dose. an adult with no known history of meningoco ccal vaccination and has anatomical	11/15/2015 F	151	deficiency Anatomical
	or			or
2016-UC-0123	functional asplenia	04/18/1992 M	160	functional asplenia
	Patient is and adult with anatomical or functional asplenia and has received the first dose of the Meningoco ccal ACWY risk 2 dose series			Anatomical or functional
2016-UC-0124		04/18/1992 M	160	asplenia

risk 2 dose or series fund	atomical
18 years of age and is seeking protection against Meningoco Pati	olenia tient
ccalB see 2016-UC-0126 disease. 01/17/1998 F 001 pro	eks otection
Meningoco stud ccal ACWY livin	llege idents ng in sidence lls

Patient is 60 years of age (vaccine naïve) and at risk during a Meningoco

ccal 2016-UC-0128 outbreak. 03/07/1956 M

Persons at risk during

an

070 outbreak

Patient is 60 years of age, at risk during a Meningoco ccal outbreak, and has received the Meningoco ccal risk 1 dose 2016-UC-0129 vaccine.	03/07/1956 M	070	Persons at risk during an outbreak			
Patient is pregnant, and at 27 weeks of gestation, and has not received the Pertussis vaccine	03/07/1936 IVI	070	outbreak			Onset of
2016-UC-0130 (Tdap) Patient is pregnant, at 27 weeks of gestation, and has received the Pertussis risk 1- dose	06/23/1988 F	007	Pregnant	04/15/2016	170	pregnancy Onset of
2016-UC-0131 vaccine.	06/23/1988 F	007	Pregnant	04/15/2016	170	pregnancy

2016-UC-0132	38 years of age, a laboratory worker who has received a completed primary series of 3 or more dose, and handles specimens that contain polioviruses 2 .	11/23/1977 M	054	Laboratory workers who handle specimens that might contain polioviruses
2016-UC-0133	Patient is a laboratory worker who has received the booster dose of the polio risk adult vaccine.	11/23/1977 M	054	Laboratory workers who handle specimens that might contain polioviruses
	Patient is 55 years of age, has no previous history of the polio vaccine, and plans on traveling to areas or countries where polio			Travel to areas or countries where polio is epidemic

2016-UC-0134 is endemic. 08/10/1961 F 143 or endemic

Patient is traveling to areas or countries where polio is endemic and has received Travel to the first areas or dose of the countries polio risk where polio adult is epidemic 2016-UC-0135 vaccine. 08/10/1961 F 143 or endemic Patient is traveling to areas or countries where polio is endemic and has received the first Travel to and second areas or dose of the countries polio risk where polio adult is epidemic or endemic 2016-UC-0136 vaccine. 08/10/1961 F 143 Patient is traveling to areas or countries where polio is an epidemic and has

Travel to

areas or

countries

where polio

is epidemic

or endemic

143

received the first,

second, and

third dose

risk adult

2016-UC-0137 vaccine.

of the polio

08/10/1961 F

Patient is a Rabies Researcher with previous history of Rabies vaccine, but has been tested and found to have a fallen	02/45/4002.5	052	Rabies
2016-UC-0138 serum titer. Patient is a Rabies Researcher with previous history of Rabies vaccine, confirmed test of a fallen serum titer, but has received the Rabies risk 3-dose continuous series booster 2016-UC-0139 dose.	02/16/1982 F	053	Rabies researchers
Patient is a new Rabies Researcher and has no previous history of			
the Rabies 2016-UC-0140 vaccine.	09/21/1986 M	053	Rabies researchers

2016-UC-0141	Patient is a new Rabies Researcher and has received the first dose of the Rabies risk 3-dose continuous vaccine series.	09/21/1986 M	053	Rabies researchers
2016-UC-0142	Patient is a new Rabies Researcher and has received the first and second dose of the Rabies risk 3-dose continuous vaccine series.	09/21/1986 M	053	Rabies researchers
	Patient is a new Rabies Researcher and has received all three doses of the Rabies risk 3-dose continuous vaccine			Rabies

09/21/1986 M

053

researchers

2016-UC-0143 series.

Patient is an animal handler with previous history of the Rabies vaccine but has been tested and found to have a fallen Animal handlers 2016-UC-0144 serum titer. 01/12/1990 F 061 Patient is an animal handler with previous history of the Rabies vaccine but has been tested and found to have a fallen serum titer and has received the booster dose of the Rabies risk 3 dose frequent Animal 2016-UC-0145 series. 061 handlers 01/12/1990 F Travel to Patient is 46 years of areas in age and which there travelling to is a an area at recognized risk of risk of exposure to exposure to 2016-UC-0146 S. Typhi. S. typhi 04/19/1970 M 163

Patient is traveling to an area at risk of exposure to

S. Typhi and

has

received

the Typhoid risk 1 dose vaccine series two weeks

before potential

2016-UC-0147 exposure.

04/19/1970 M

163

Travel to areas in which there

is a

recognized risk of

exposure to S. typhi

Two years later, patient continues to travel to an area at risk of

exposure to

S. Typhi and has received the booster dose of the

Typhoid risk 1-dose

2016-UC-0148 series.

04/19/1970 M

163

Travel to areas in which there is a

recognized risk of exposure to

S. typhi

Patient is a microbiolog

laboratoria n who works frequently

with S. typhi

2016-UC-0149 carrier.

10/15/1980 M

Microbiolog

У

laboratoria ns who work frequently with S.

typhi

051

Patient is a microbiolog

У

laboratoria n who works frequently with S.

typhi

carrier and

has received the Risk 4 dose Vaccine

2016-UC-0150 series.

10/15/1980 M

051

Microbiolog

У

laboratoria ns who work frequently with S.

typhi

Patient is 52 years of age and travelling to a country at risk for Yellow Fever

transmissio

2016-UC-0151 n.

07/01/1964 F

Travel to areas at risk for Yellow Fever transmissio

7/01/1964 F 162 n

2016-UC-0152	Patient is travelling to a country at risk for Yellow Fever transmissio n and has received the Yellow Fever risk 1 dose series.	07/01/1964 F	162	Travel to areas at risk for Yellow Fever transmissio n
	years old with cochlear implants, and has an incomplete schedule (only received 1 dose) of the			
2016-UC-0153	PCV 13 series. Patient is 19 years of age and	01/08/2013 M	011	Cochlear implants
2016-UC-0157	smokes cigarettes.	03/08/1997 F	042	Smoke cigarettes

years of age with cerebrospin al fluid leaks and has not received (vaccine naive)PCV1 Cerebrospi 3 nor nal fluid PPSV23 2016-UC-0159 vaccine. 09/14/2008 M 010 leaks Patient is 8 years of age and has cerebrospin al fluid leaks and has received the PCV13 vaccine but not the Cerebrospi PPSV23 nal fluid 2016-UC-0160 vaccine. 09/14/2008 M 010 leaks Patient is 15 years of age and has cerebrospin al fluid leaks and has received a dose of the PPSV23 vaccine but not the Cerebrospi PCV13 nal fluid 2016-UC-0162 vaccine. 03/16/2001 F 010 leaks

	Patient is 39 years of age, has cochlear implants, and has received the PPSV23 vaccine but not PCV13.	05/01/1977 M	011	Cochlear implants
	Patient is 9 years of age, has HIV infection, and has received a dose of PPSV23 vaccine but has not received a dose of the PCV 13			HIV/AIDS - not severely immunoco
2016-UC-0169		04/13/2007 M	155	mpromised HIV/AIDS - not severely immunoco
2016-U C-0170	later.	04/13/2007 M	155	mpromised

2016-UC-0172	Patient is 22 years of age and has General malignant neoplasm and has received a dose of PPSV23 but not PCV13.	06/13/1994 M	156	Generalized malignant neoplasm
2016-UC-0173	Patient is 22 years of age and has General malignant neoplasm and has received a dose of PPSV23 and a dose PCV13 one year later.	06/13/1994 M	156	Generalized malignant neoplasm
2016-UC-0175	Patient is 14 years of age and has Persistent Component , properdin, or Factor B deficiency, has previously received 2 doses of the PPSV23 vaccine but has not received a dose of PCV13.	04/04/2002 F	151	Persistent complemen t, properdin, or factor B deficiency

Patient is 25 years of age with nephrotic syndrome, has previously received two doses of PPSV23 vaccine but has not received a dose of the PCV13 2016-UC-0177 vaccine. Patient is a traveler who plans to spend a	07/02/1986 M	167	Nephrotic Syndrome		
month or longer in an endemic area and has experience d a severe allergic reaction after previous dose of Japanese Encephalitis 2016-UC-0179 vaccine.	12/10/1977 M	082	Severe allergic reaction after previous dose of Japanese Encephalitis	165	Travelers who plan to spend a month or longer in endemic areas during the JE virus transmissio n season
Patient is a traveler who plans to spend a month in an endemic area and has had an adverse reaction to a vaccine component of Japanese Encephalitis 2016-UC-0180 vaccine.	08/19/1981 F	080	Adverse reaction to vaccine component	165	Travelers who plan to spend a month or longer in endemic areas during the JE virus transmissio n season

	Patient is an animal handler with no previous history of the Rabies			Animal
2016-UC-0181		09/24/1976 M	061	handlers
2016-UC-0182		09/24/1976 M	061	handlers
2016-UC-0183		09/24/1976 M	061	handlers
2016-UC-0184	vaccine series.	09/24/1976 M	061	Animal handlers

veterinaria n staffer and has experience d a severe allergic reaction after previous dose of Rabies 2016-UC-0185 vaccine.	05/13/1984 F	113	Severe allergic reaction after previous dose of Rabies	060	Veterinaria ns and their staff
Patient has adverse reaction to vaccine 2016-UC-0186 component	03/17/1986 F	080	Adverse reaction to vaccine component	060	Veterinaria ns and their staff rraver to country with a Yellow
experience d a severe allergic reaction to 2016-UC-0187 egg protein.	12/15/1968 M	101	Allergic reaction to egg protein	045	Fever vaccination entry requiremen t

5 years later microbiolog y laboratoria n receives a booster dose of the Typhoid risk 4 dose			Microbiolog y laboratoria ns who work frequently with S.		
2016-UC-0188 vaccine microbiolog y laboratoria n who has experience a severe allergic reaction after previous dose of Typhoid	03/10/1977 F	051	Severe allergic reaction after previous dose of		Microbiolog y laboratoria ns who work frequently with S.
Patient is 22 years of age smokes and has	10/08/1972 M	084	Typhoid	051	typhi Smoke
2016-UC-0190 asthma	07/22/1994 M	027	Asthma	042	cigarettes

Patient is a smoker, has diabetes, and asthma and has not received the Pneumococ cal risk 1 dose					
2016-UC-0192 vaccine. 28 years of age, is MSM, has HIV, is an	08/14/1965 M	014	Diabetes	027	Asthma
illicit drug user, and has not been vaccinated					HIV/AIDS - not
with the Hep B			Men who have sex		severely immunoco
2016-UC-0194 vaccine. MSM, has HIV, is an illicit drug user, and has received	03/23/1988 M	036	with men	155	mpromised
the first dose of the Hep B Risk 3-dose			Men who have sex		HIV/AIDS - not severely immunoco
2016-UC-0195 series Patient is MSM, has HIV, is an illicit drug user, and has received the first	03/23/1988 M	036	with men	155	mpromised
and second dose of the Hep B Risk 3-dose			Men who have sex		HIV/AIDS - not severely immunoco
2016-UC-0196 series	03/23/1988 M	036	with men	155	mpromised

MSM, has HIV, is an illicit drug user, and has received the first, second, and third of the Hep B Risk 3-dose 2016-UC-0197 series	03/23/1988 M	036	Men who have sex with men	155	HIV/AIDS - not severely immunoco mpromised
Patient is 39 years of age, a microbiolog ist who is frequently exposed to Neisseria meningitidi s, and who plans to travel to countries where meningoco ccal disease			Microbiolog ists routinely exposed to Neisseria meningitidi		Travel to or are residents of countries in which meningoco ccal disease is hyperende mic or
2016-UC-0198 is endemic. had a previous severe allergic reaction to vaccine ingredient yeast	07/13/1977 F	050	s Hypersensit ivity to	164	epidemic
2016-UC-0200 (Energix B) an animal handler who has had a previous severe allergic reaction to vaccine ingredient to chicken protein	04/28/1949 M	110	Severe allergic reaction to chicken		Animal
2016-UC-0201 (RabAvert)	03/21/1979 M	105	protein	061	handlers

	Patient is pregnant, and does not have evidence of immunity from Rubella					
2016-UC-0202	disease. Patient is seeking protection, and has had a severe	06/01/1985 F	007	Pregnant		
	allergic reaction after previous dose of Meningoco ccal B			Severe allergic reaction after previous dose of Meningoco		Patient seeks
2016-UC-0203		01/13/1995 M	116	ccal B	001	protection
	doses at least 6 months			History of sexual abuse or		
2017-UC-0001	Patient is 15 years of age, with a history of sexual assault, and has not received any previous	07/12/2006 F	169	assault History of		
	doses of			sexual		
2017-UC-0002	the HPV vaccine.	10/01/2001 M	169	abuse or assault		

Patient is 15 years of age, with a history of sexual assault, and has received the first dose of the HPV

HPV sexual vaccine 3 abuse or 2017-UC-0003 dose series 10/01/2001 M 169 assault

History of

History of

History of

sexual

Patient is
15 years of
age, with a
history of
sexual
assault, and
has
received
the first
and second
dose of the

3 dose HPV sexual vaccine abuse or 2017-UC-0004 series. 10/01/2001 M 169 assault

Patient is 15 years of age, with a history of sexual assault, and has received the first, second, and third dose of the 3

dose HPV

vaccine abuse or 2017-UC-0005 series. 10/01/2001 M 169 assault

	Patient is an adolescent child, with a history of sexual assault with first dose of HPV vaccine at 13 years and second dose after 15 years of			History of sexual abuse or
2017-UC-0006		04/12/2001 F	169	assault
	Patient is 11 years of age, immunoco mpromised, and has not received any previous			Canadian
	does of the HPV			Generalized malignant
2017-UC-0007	Patient is 11 years of age, immunoco mpromised, and has received the first dose of the HPV 3 dose	06/02/2005 F	156	neoplasm
2017-UC-0008	vaccine series.	06/02/2005 F	156	malignant neoplasm
2017 00 0000		33, 32, 2003 1		

Patient is 11 years of age, immunoco mpromised, and has received the first and second dose of the HPV 3 dose vaccine	05/03/2025 5	156	Generalized malignant
2017-UC-0009 series. Patient is 11 years of age, immunoco mpromised, and has received the first, second, and third dose	06/02/2005 F	156	neoplasm
of the HPV 3 dose vaccine 2017-UC-0010 series.	06/02/2005 F	156	Generalized malignant neoplasm
Patient is an adult with persistent complemen t component deficiences and has not received any			Persistent complemen
previous doses of the Men B 2017-UC-0011 vaccine	09/02/1995 M	151	t, properdin, or factor B deficiency

	Patient is an adult with persistent complemen t component deficiences and has			Persistent
2017-UC-0012	received the first dose of the 2 dose Men 8 B vaccine	09/02/1995 M	151	t, properdin, or factor B deficiency
		,,		,
	Patient is an adult with persistent complemen t component deficiences and has received the first			Persistent complemen
	and second dose of the			t, properdin,
2017-UC-0013	2 dose Men B vaccine	09/02/1995 M	151	or factor B deficiency
	Patient is 38 years of age, a			
2017 LIC 0014	microbiolog ist who has received a dose of the MenACWY. 5 years has	07/12/1077 F	50	Microbiolog ists routinely exposed to Neisseria meningitidi
2017-UC-0014	+ hast	07/13/1977 F	50	S

Patient is
35 years of
age and is
traveling to
a country
that has
active
cholera
transmissio

Travel to an area of active cholera transmissio

2017-UC-0015 n. 02/17/1982 M 8

Patient is 35 years of age and is traveling to a country that has active cholera transmissio

transmissio Travel to an n and has area of received active the Cholera cholera 1-dose transmissio

2017-UC-0016 series. 02/17/1982 M 8 n

Patient is 28 years of age and has had an adverse reaction to

reaction to Adverse
a vaccine reaction to
component vaccine
2017-UC-0017 in Cholera. 08/01/1989 M 80 component

Not Complet 04/02/2001 DTaP Unspec 107

Contraindica 12/10/2010 DTaP Unspec 107

Not Complet 04/02/2011 PEDIARIX 110 SKB

Contraindica 12/15/2010 PEDIARIX 110 SKB

Contraindica 08/02/2010 PENTACEL 120 PMC

Contraindica 10/08/2014 Influenza Un 88

Contraindica	03/04/2009 Hep A Unsp∈85
--------------	--------------------------

Contraindica 11/11/2006 RECOMBIVA 08	1SD
--------------------------------------	-----

Contraindica 06/19/2011 HPV Unspeci 137

Contraindica 03/15/2011 Meningococ 147

Contraindica 09/02/2011 M-M-R II 03 MSD

Contraindicated

Contraindica	09/11/2007	PREVNAR 7	100	WAL
Contraindica	09/24/2011	IPOL	10	PMC

Contraindicated

Contraindica 04/01/2012 ROTARIX 119 SKB

Contraindica 04/01/2012 ROTATEQ 116 MSD

Immune

Immune

Contraindica	03/15/2012 VARIVAX	21	MSD
Contraindica	12/20/2010 VARIVAX	21	MSD
Contraindicate	d		
Immune			
Immune			
Immune			

Not Complet 05/28/2015 VARIVAX 21 MSD

Complete 07/03/2012 VARIVAX 21 MSD

Contraindicated

Contraindicated

Contraindicated

04/30/2015 M-M-R II 03 MSD Immune

Not Complete

Not Complet 07/01/2016 Hep A, adult 52 MSD

Not Complet 08/01/2016 HepA-HepB 104

Not Complet 04/01/2016 HepA-HepB 104 SKB

SKB

Not Complet 03/12/2016 HepA-HepB 104 SKB

Not Complet 05/17/2016 HepA-HepB 104 SKB

Complete 05/17/2016 HepA-HepB 104 SKB

Not Complete

Not Complet 04/22/2016 Hep B, Dialy: 44

MSD

Not Complet 04/22/2016 Hep B, Dialys 44 MSD

Complete 05/15/2016 Hep B, Dialy: 44 MSD

Not Complet 03/13/2016 Hep B, Adult 43

Not Complet 03/13/2016 Hep B, Adult 43 SKB

SKB

03/13/2016 Hep B, Adult 43 Complete

SKB

Not Complete

Not Complet 08/08/2016 PRP-T 48

PMC

Complete 08/08/2016 PRP-T 48 PMC

Not Complet 01/10/2015 PRP-OMP 49 MSD

Not Complet 01/10/2015 PRP-OMP 49 MSD

Complete 01/10/2015 PRP-OMP 49 MSD

Not Complet 06/10/2013 PRP-T 48 PMC

Complete 06/10/2013 PRP-T 48 PMC

Complete 07/01/2016 PRP-OMP 49 MSD

Not Complete

Complete 08/03/2016 PRP-OMP 49 MSD

Complete 02/03/2016 PRP-OMP 49

MSD

Not Complete

Not Complet 09/19/2014 PRP-T 48 PMC

Not Complet 09/19/2014 PRP-T 48 PMC

Complete 06/01/2014 PRP-T 48 PMC

Not Complet 07/25/2016 PRP-T 48 PMC

Not Complet 07/25/2016 PRP-T 48 PMC

Not Complet 12/15/2016 9vHPV 165 MSD

Complete 12/19/2016 9vHPV 165 MSD

Not Complet 12/23/2016 9vHPV 062 MSD

Complete 05/17/2016 9vHPV 165 MSD

Not Complete

Not Complet 07/21/2016 9vHPV 165 MSD

Not Complet 04/03/2014 4vHPV 062 MSD

Complete 03/28/2015 4vHPV 062 MSD



Not Complet 08/15/2016 Japanese En 134

VAL

Complete

04/28/2016 Japanese En₁34

VAL

Not Complet 05/12/1997 MMR 03 MSD

Not Complet 05/12/1997 MMR 03 MSD

Complete 05/12/1997 MMR 03 MSD

Not Complete

Complete 07/04/2016 meningococ 163

NOV

Not Complete

Not Complet

03/28/2016 meningococ 163

NOV

Complete 03/28/2016 meningococ 163 NOV

Not Complete

Not Complet 06/23/2016 meningococ 162 PFR

Complete 06/01/2016 meningococ 162

PFR

Not Complete

Not Complet 04/14/2015 Meningococ 136

NOV

Not Complet 04/14/2015 Meningococ 136 NOV

Not Complet 04/14/2015 Meningococ 136 NOV

Not Complet 04/14/2015 Meningococ 136 NOV

Not Complet 10/23/2012 Meningococ 136 NOV

Not Complet 03/01/2007 Meningococ 136

NOV

Not Complete

Not Complet 12/10/2015 Meningococ 136 NOV

Not Complet 09/28/2015 Meningococ 148

SKB

Not Complet 09/28/2015 Meningococ 148 SKB

Not Complet 09/28/2015 Meningococ 148

SKB

Not Complet 01/15/2016 Meningococ 148

SKB

Not Complete

Not Complet 05/02/2016 Meningococ 136

NOV

Not Complete

Complete 01/17/2016 Meningococ 114

PMC



Complete 05/23/2016 Meningococ 32 PMC

Not Complete

Not Complet 01/23/1978 IPV 10 PMC

Complete 01/23/1978 IPV 10 PMC

Not Complete

Not Complet 09/05/2016 IPV 10 PMC

Not Complet 09/05/2016 IPV 10 PMC

Complete 09/05/2016 IPV 10 PMC

Not Complet 06/28/2015 Rabies, intra 18

NOV

Complete 06/28/2015 Rabies, intra 18 NOV

Not Complete

Not Complet 05/16/2016 Rabies, intra 18 PMC

Not Complet 05/16/2016 Rabies, intra 18 PMC

Complete 05/16/2016 Rabies, intra 18 PMC

Not Complet 06/18/2015 Rabies, intra 18

PMC

Complete 06/18/2015 Rabies, intra 18

PMC

Not Complete

Not Complet 07/22/2016 Typhoid cap: 101

PMC

Not Complet 07/22/2016 Typhoid cap: 101

PMC



Not Complet 08/16/2016 Typhoid cap: 101

PMC



Complete 09/01/2016 Yellow Fever 37 PMC

Not Complet 05/08/2013 PCV 13 133 PFR

Not Complete

Not Complete

Not Complet 09/14/2016 PCV 13 133 PFR

Not Complet 05/02/2016 PPSV 23 33 MSD

Not Complet 08/01/2016 PPSV 23 33 MSD

Not Complet 06/01/2016 PPSV 23 33 MSD

Not Complet 06/01/2016 PPSV 23 33 MSD

Not Complet 08/21/2016 PPSV 23 33 MSD

Not Complet 08/21/2016 PPSV 23 33 MSD

Not Complet 08/03/2006 PPSV 23 33 MSD

Contraindica 05/15/2016 Japanese En 134 VAL

Not Complete

Not Complet 08/01/2016 Rabies, intra 18 NOV

Not Complet 08/01/2016 Rabies, intra 18 NOV

Complete 08/01/2016 Rabies, intra 18 NOV

Contraindica	07/29/2016 Rabies, intra 18	NOV
--------------	-----------------------------	-----

Contraindica 01/13/2016 Rabies, intra 18	NOV
--	-----

Contraindicated

Not Complet 07/10/2016 Typhoid cap: 101 PMC

Contraindica 08/15/2016 Typhoid cap: 101 PMC

Not Complete

Smoke 042 cigarettes Not Complete Illicit injection 041 drug use Not Complete Illicit injection drug use 041 Not Complet 05/19/2016 Hep B, Adult 43 MSD

Not Complet

05/19/2016 Hep B, Adult 43

MSD

Illicit injection

drug use

041

Illicit injection

041

drug use Complete 05/19/2016 Hep B, Adult 43

Not Complete

Contraindica 05/17/2015 Hep B, Adult 43 SKB

 MSD

Contraindicated

Contraindica 06/28/2016 meningococ 163

Complete 07/12/2015 9vHPV 165 MSD

Not Complet 01/08/2017 9vHPV 165 MSD

Not Complet 01/08/2017 9vHPV 165 MSD

Complete 01/08/2017 9vHPV 165 MSD

Complete 07/13/2014 4vHPV 62 MSD

Not Complete

Not Complet 08/01/2016 9vHPV 165 MSD

Not Complet 08/01/2016 9vHPV 165 MSD

Complete 08/01/2016 9vHPV 165 MSD

Not Complete

Not Complet 03/02/2017 meningococ 163 NOV

Complete 03/02/2017 meningococ 163 NOV

Not Complet 06/01/2016 Meningococ 114 PMC

Not Complete

Complete 07/18/2017 Cholera 174 PAX

Contraindicated

Evaluation_ Evaluation_ Date_Admi Vaccine_Na CVX_2		MVX_2	Evaluation_Evaluation_Date_Admi		
١	Valid	06/02/2001 DT(GENERIC 28	РМС	Valid	08/02/2001
١	Valid				
,	Valid				
,	Valid				
,	Valid				
,	Valid				

Valid Valid Valid Valid Valid Valid

Valid

Valid

Valid 05/01/2012 ROTARIX 119 SKB Valid

Valid

Valid 07/31/2012 Varivax 21 Valid

Valid

Valid 04/29/2016 HepA-HepB 104 SKB Valid

Valid 09/02/2016 HepA-HepB 104

SKB

Valid

02/02/2017

Valid

05/24/2016 HepA-HepB 104

SKB

Valid

Valid 05/24/2016 HepA-HepB 104 SKB Valid 06/07/2016

Valid 05/20/2016 Hep B, Dialy: 44 Valid MSD Valid

11/12/2016

Valid

MSD

06/12/2016 Hep B, Dialy: 44

Valid

Valid 04/10/2016 Hep B, Adult 43 SKB Valid

Valid

04/10/2016 Hep B, Adult 43

SKB

Valid

05/08/2016

04/10/2016 Hep B, Adult 43

SKB

Valid

05/08/2016

Valid

Valid 10/03/2016 PRP-T 48 PMC Valid

Valid 04/13/2016 PRP-OMP 49 MSD Valid

Valid 04/13/2016 PRP-OMP 49 MSD Valid 06/08/2016

Valid 07/08/2013 PRP-T 48 PMC Valid

Valid 07/08/2013 PRP-T 48 PMC Valid 05/14/2016



Valid 10/17/2014 PRP-T 48 PMC Valid

Valid 06/29/2014 PRP-T 48 PMC Valid 07/27/2014

Valid 08/22/2016 PRP-T 48 PMC Valid

Valid 08/22/2016 PRP-T 48 PMC Valid 09/19/2016

Valid 06/01/2017 9vHPV 165 MSD Valid

Valid 06/14/2016 9vHPV 165 MSD Valid 11/01/2016



062

MSD

Valid

09/14/2015

Valid

04/25/2015 4vHPV



05/26/2016 Japanese En 134

VAL

Valid

Valid 05/12/2000 MMR 03 MSD Valid

Valid 05/12/2000 MMR 03 MSD Valid 06/12/2016

Valid 05/12/2000 MMR 03 MSD Valid 06/12/2016

Valid 08/01/2016 meningococ 163

NOV

Valid

04/25/2016 meningococ 163 Valid NOV Valid

07/27/2016 meningococ 162

PFR Valid

12/01/2016

Valid

Valid 06/09/2015 Meningococ 136 NOV Valid

Valid 06/09/2015 Meningococ 136 NOV Valid 08/04/2015

Valid 06/09/2015 Meningococ 136 NOV Valid 08/04/2015

Valid 12/18/2012 Meningococ 136 NOV Valid 02/12/2013

Valid 04/26/2007 Meningococ 136 NOV Valid 06/21/2007

Valid 11/23/2015 Meningococ 148 SKB Valid 01/18/2016

SKB

Valid

01/18/2016

11/23/2015 Meningococ 148

Valid 03/11/2016 Meningococ 148

SKB

Valid

05/06/2016

Valid 06/27/2016 Meningococ 136

NOV

Valid



Valid	02/20/1978 IPV	10	PMC	Valid	11/23/1978
Valid	02/20/1978 IPV	10	PMC	Valid	11/23/1978

Valid

Valid

10/03/2016 IPV 10 PMC Valid

Valid 10/03/2016 IPV 10 PMC Valid 04/03/2017



Valid

Valid

05/23/2016 Rabies, intra 18

PMC

Valid

PMC

Valid

06/06/2016

05/23/2016 Rabies, intra 18

Valid 06/25/2015 Rabies, intra 18 PMC Valid 07/09/2015

PMC

Valid

06/25/2015 Rabies, intra 18

Valid

07/09/2015



07/22/2018 Typhoid cap: 101

Valid

PMC





Valid

Valid 07/27/2016 PCV 13 133 PFR Valid

Valid 08/21/2017 PCV 13 133 PFR Valid

Valid 04/16/2016 PPSV 23 33 MSD Valid

Valid 08/03/2011 PPSV 23 33 MSD Valid



07/10/2021 Typhoid cap: 101

PMC

Valid

Valid 06/16/2016 Hep B, Adult 43

MSD

Valid

08/11/2016

Valid 01/23/2016 9vHPV 165 MSD Valid

Valid 02/05/2017 9vHPV 165 MSD Valid

165

MSD

Valid

06/08/2017

02/05/2017 9vHPV

Valid 03/28/2017 9vHPV 165 MSD Valid

Valid 08/29/2016 9vHPV 165 MSD Valid

Valid 08/29/2016 9vHPV 165 MSD Valid 01/23/2017

Valid 03/30/2017 meningococ 163

NOV

Valid



Vaccine_Ni CVX_3 MVX_3 Evaluation_ Evaluation_ Date_Admi Vaccine_Ni CVX_4 MVX_4

DT(GENERIC 28 PMC Valid 05/02/2002 DT(GENERIC 28 PMC

HepA-HepB 104 SKB Valid

HepA-HepB 104 SKB Valid 06/17/2017 HepA-HepB 104

SKB

Hep B, Adult 43

SKB

Valid

09/08/2016 Hep B, Adult 43

SKB

PRP-OMP 49 MSD Valid

PRP-T 48 PMC Valid

PRP-T 48 PMC Valid

9vHPV 165 MSD Valid

4vHPV 62 MSD Valid

MMR 03 MSD Valid

MMR 03 MSD Valid 07/10/2016 MMR 03 MSD

meningococ 162

PFR

Valid

Meningococ 136

NOV

Valid

 Meningococ 136
 NOV
 Valid
 02/14/2016 Meningococ 136
 NOV

 Meningococ 136
 NOV
 Valid
 08/23/2013 Meningococ 136
 NOV

Meningococ 136 NOV Valid 01/01/2008 Meningococ 136 NOV

Meningococ 148 SKB Valid

Meningococ 148 SKB Valid 07/2

07/18/2016 Meningococ 148

SKB

Meningococ 148 SKB Valid 11/06/2016 Meningococ 148 SKB

IPV	10	PMC	Valid	02/02/1982 IPV	10	РМС
IPV	10	PMC	Valid	02/02/1982 IPV	10	PMC

IPV 10 PMC Valid

Rabies, intra 18 NOV Valid

Rabies, intra 18 NOV Valid 01/19/2016 Rabies, intra 18 NOV

Rabies, intra 18

PMC

Valid

Rabies, intra 18 PMC Valid

Rabies, intra 18 PMC Valid 07/19/2

07/19/2017 Rabies, intra 18

PMC

Valid

Hep B, Adult 43

MSD

Valid

9vHPV 165 MSD Valid

9vHPV 165 MSD Valid

Evaluation_ Evaluation_ Date_Admi Vaccine_N; CVX_5 MVX_5 Evaluation_ Evaluation_ Date_Admi

PMC

Valid

05/05/2006 DT(GENERIC 28

Valid







Valid

Valid

08/23/2016 Meningococ 136

NOV

Valid

Valid 01/01/2011 Meningococ 136 NOV Valid 01/01/2016



11/06/2019 Meningococ 136

Valid

NOV

Valid

Valid

Valid 04/04/2016 IPV 10 PMC Valid





MVX_7

Meningococ 136

NOV

Valid

6 02/02/2012 02/02/2012 02/01/2014	DTaP	05/05/2006
-	DTaP	12/10/2010
2 04/30/2011 06/02/2011 07/29/2011	DTaP	04/02/2011
2 0 1/35/2011 05/52/2011 07/25/2011	D rui	0 1/ 02/ 2011
-	DTaP	12/15/2010
-	DTaP	08/02/2010
-	Flu	10/08/2014

03/04/2009 НерА 11/11/2006 НерВ 08/02/2010 Hib HPV 06/19/2011 Meningococ 03/15/2011 09/02/2011 MMR

09/10/2011

MMR

Pneumoccoc 09/11/2007

POL 09/24/2011

- Rota 03/01/2012

Rota 04/01/2012

Rota 05/01/2012

Var 04/01/2005

- Var 06/01/2006

- Var 03/15/2012

- Var 12/20/2010

Var 10/18/2011

Var 06/16/2015

Var 06/16/2015

Var 06/19/2015

2 06/25/2015 06/25/2015 07/23/2015 Var 05/28/2015

Var 06/01/2015

Var 06/19/2015

06/12/2015 Zoster

Zoster 06/16/2015

Includes the MMR 04/30/2015

1 04/01/1986 04/01/1986 04/28/1987 HepA 04/23/2016

2 01/01/2017 01/01/2017 HepA 07/01/2016

- HepA 11/01/2016

1 04/12/1962 04/12/1962 05/09/1963

НерА

08/01/2016

2 08/29/2016 08/29/2016

НерА

08/01/2016

3 10/29/2016 10/29/2016

НерА

04/29/2016

HepA 02/02/2017

1 01/12/2009 01/12/2009

HepB 03/12/2016

2 03/19/2016 03/19/2016

HepB 03/12/2016

4 06/07/2017 06/07/2017

НерВ

06/07/2016

HepB 06/07/2017

1 01/17/1985 01/17/1985

НерВ

04/22/2016

2 05/20/2016 05/20/2016

HepB 04/22/2016

3 10/20/2016 10/20/2016

HepB 05/20/2016

HepB 11/12/2016

1 02/13/1966 02/13/1966 HepB 03/13/2016

2 04/10/2016 04/10/2016 HepB 03/13/2016

- HepB 06/05/2016

1 07/15/2015 07/15/2015 Hib 08/08/2016

2 10/03/2016 10/03/2016 Hib 08/08/2016

Hib 10/03/2016

2 03/07/2015 03/07/2015

Hib 04/13/2016

3 06/08/2016 06/08/2016

Hib

04/13/2016

Hib 06/08/2016

3 05/14/2016 05/14/2016

Hib 05/14/2016

Hib 05/14/2016

1 09/22/2010 09/22/2010

Vaccination Hib 07/01/2016

Vaccination Hib

07/01/2016

1 10/10/1998 10/10/1998 Vaccination Hib

08/03/2016

Vaccination Hib

08/03/2016

1 07/23/2004 07/23/2004	Hib	02/03/2016
-	Hib	02/03/2016
1 09/25/2010 09/25/2010	At least 4 wε Hib	09/19/2014

3 11/14/2014 11/14/2014 At least 4 wε Hib 10/17/2014

At least 4 wε Hib 07/27/2014

2 08/22/2016 08/22/2016

At least 4 w∈ Hib

07/25/2016

3 09/19/2016 09/19/2016 At least 4 wε Hib

08/22/2016

1 04/04/2016 04/04/2018 04/04/2018

HPV 01/09/2017

2 05/15/2017 06/15/2017

HPV 12/15/2016

HPV 06/01/2017

1 02/15/2016 02/15/2016 02/14/2018

HPV 11/17/2016

2 05/23/2017 06/23/2017

HPV

12/23/2016

HPV

11/01/2016

1 02/02/2003 02/02/2005 03/01/2007 HPV

02/02/2016

2 08/18/2016 09/15/2016 11/09/2016

HPV 07/21/2016

3 09/03/2014 10/03/2014 11/30/2014 HPV 06/13/2016

HPV 09/14/2015

. . - . .

recommen

ds that if

the primary

series of JE-

VC was

administere

d greater

than 1 year

previously,

a booster

dose may

be given

before

potential JE

virus

exposure.

ACIP

recommen

dations

should be

consulted

for

information

on

prevention

of JE and

settings in

which JE

vaccine is

1 09/01/1984 09/01/1984

recommen Japanese En 08/15/2016

recommen

ds that if

the primary

series of JE-

VC was

administere

d greater

than 1 year

previously,

a booster

dose may

be given

before

potential JE

virus

exposure.

ACIP

recommen

dations

should be

consulted

for

information

on

prevention

of JE and

settings in

which JE

vaccine is

2 09/12/2016 09/12/2016

recommen Japanese En 08/15/2016

recommen ds that if the primary series of JE-VC was administere d greater than 1 year previously, a booster dose may be given before

potential JE

virus

exposure.

ACIP

recommen

dations

should be

consulted

for

information

on

prevention

of JE and

settings in

which JE

vaccine is

recommen Japanese En 08/23/2016

2 02/28/2017 02/28/2017

Children who MMR 08/28/2016

3 05/12/2014 05/12/2014

MMR

06/12/2016

4 07/10/2016 07/10/2016

MMR

06/12/2016

MMR 07/10/2016

1 07/04/2014 07/04/2014 MMR 07/04/2016

MenB 08/01/2016

1 03/28/2016 03/28/2016 MenB 03/28/2016

2 04/25/2016 04/25/2016 MenB 03/28/2016

- MenB 04/25/2016 1 10/01/1986 10/01/1986 MenB 06/23/2016

2 08/18/2016 08/18/2016 MenB 06/23/2016

- MenB 10/23/2016

1 04/14/2015 04/14/2015 If MenACWY Meningococ 04/14/2015

2 06/09/2015 06/09/2015

If MenACWY Meningococ 04/14/2015

3 08/04/2015 08/04/2015 If MenACWY Meningococ 06/09/2015

4 02/04/2016 02/04/2016 If MenACWY Meningococ 08/04/2015

5 02/14/2019 02/14/2019 If MenACWY Meningococ 02/14/2016


6 08/23/2021 08/23/2021 If MenACWY Meningococ 08/23/2016

7 01/01/2021 01/01/2021 If MenACWY Meningococ 01/01/2016

1 12/10/2015 12/10/2015 If MenACWY Meningococ 12/10/2015

2 03/03/2016 03/03/2016

If MenACWY Meningococ 12/10/2015



3 01/18/2016 01/18/2016 If MenACWY Meningococ 11/23/2015

4 07/18/2016 07/18/2016 If MenACWY Meningococ 01/18/2016

5 07/18/2019 07/18/2019 If MenACWY Meningococ 07/18/2016

6 11/06/2024 11/06/2024 If MenACWY Meningococ 11/06/2019 1 04/18/1994 04/18/1994 If MenACWY Meningococ 05/02/2016

3 06/27/2021 06/27/2021 If MenACWY Meningococ 06/27/2016

1 01/17/2014 01/17/2014 A MenB vacc MenB 08/30/2016

If persons 56 years older are expected to receive a single dose, then polysacchar ide vaccine should be used.

If persons
56 years
older are
expected to
receive
multiple
doses, then
conjugate
vaccine
should be
used in
place of the
polysacchar

1 03/07/1958 03/07/1958

ide vaccine. Meningococ 08/30/2016

If persons 56 years older are expected to receive a single dose, then polysacchar ide vaccine should be used.

If persons
56 years
older are
expected to
receive
multiple
doses, then
conjugate
vaccine
should be
used in
place of the
polysacchar

ide vaccine. Meningococ 05/23/2016

08/22/2016 10/24/2016 Administer c Tdap

1

08/22/2016

5 11/23/1995 11/23/1995 IPOL 04/04/2016

- IPOL 04/04/2016

2 10/03/2016 10/03/2016

IPOL 09/05/2016

3 04/03/2017 05/03/2017

IPOL 10/03/2016

IPOL 04/03/2017

4 01/19/2016 01/19/2016 The 6 month Rabies 07/19/2015

The 6 month Rabies 01/19/2016

1 05/16/2016 05/16/2016 Rabies 05/16/2016

2 05/23/2016 05/23/2016

Rabies 05/16/2016

3 06/06/2016 06/06/2016

Rabies 05/23/2016

The 6 month Rabies 06/06/2016

4 07/09/2017 07/09/2017 The 2 year b Rabies 07/09/2015

- The 2 year b Rabies 07/09/2017

07/22/2016

IPOL

1 04/19/1972 04/19/1972

Primary vaccination with liveattenuated Ty21a vaccine consists of one entericcoated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept

2 07/22/2018 07/22/2018

refrigerated Typhoid

07/22/2016

Primary vaccination with liveattenuated Ty21a vaccine consists of one entericcoated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept

3 07/22/2020 07/22/2020

refrigerated Typhoid

07/22/2018

Primary vaccination with liveattenuated Ty21a vaccine consists of one entericcoated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept

1 10/15/1998 10/15/1998

refrigerated Typhoid

08/16/2016

Primary vaccination with liveattenuated Ty21a vaccine consists of one entericcoated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept

2 08/16/2021 08/16/2021

refrigerated Typhoid

08/16/2016

- - - - - - primary

dose of

yellow

fever

vaccine

provides

long-lasting

protection

and is

adequate

for most

travelers

but

additional

doses of

yellow

fever

vaccine are

recommen

ded for

certain

travelers

with

ongoing

risk.

Women

who were

pregnant

(regardless Yellow Fever 09/01/2016

1 04/01/1965 04/01/1965

primary dose of yellow fever vaccine

provides long-lasting

protection

and is

adequate

for most

travelers

but

additional

doses of yellow

fever

vaccine are

recommen

ded for

certain

travelers

with

ongoing

risk.

Women

who were

pregnant

(regardless Yellow Fever 09/01/2016

2 01/08/2015 01/08/2015

When cochle Pneumoccoc 02/12/2016

1 03/08/2003 03/08/2003 03/08/2062

Pneumoccoc 04/16/2016

1 09/14/2014 09/14/2014

Pneumoccoc 09/14/2016

2 11/09/2016 11/09/2016

Pneumoccoc 09/14/2016

2 06/27/2016 06/27/2016

Pneumoccoc 05/02/2016

2 08/01/2017 08/01/2017 When cochic Pneumoccoc 08/01/2016
2 07/27/2016 07/27/2016 Pneumoccoc 06/01/2016

Pneumoccoc 07/27/2016

3 06/01/2021 06/01/2021

2 08/21/2017 08/21/2017

Pneumoccoc 08/21/2016

3 08/21/2021 08/21/2021

Pneumoccoc 08/21/2016

3 08/03/2012 08/03/2012

Pneumoccoc 08/03/2011

Japanese En 05/15/2016

1 09/28/1976 09/28/1976 Rabies 08/01/2016
2 08/08/2016 08/08/2016 Rabies 08/08/2016
3 08/22/2016 08/22/2016 Rabies 08/08/2016

The 2 year b Rabies 08/22/2016

Rabies 07/29/2016

Rabies 01/13/2016

Yellow Fever 03/13/2016

Primary vaccination with liveattenuated Ty21a vaccine consists of one entericcoated capsule taken on alternatedays (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept

3 07/10/2026 07/10/2026

refrigerated Typhoid

07/10/2021

Typhoid 08/15/2016

1 07/22/2000 07/22/2000

Pneumoccoc 10/13/2016

1 08/14/1971 08/14/1971 08/14/2030 Pneumoccoc 07/12/2016

1 03/23/2007 03/23/2007 HepB 05/19/2016

2 06/16/2016 06/16/2016

HepB 05/19/2016

HepB 08/11/2016

1 07/13/1996 07/13/1996 Meningococ 08/02/2016

HepB 02/12/2016

- Rabies 04/27/2016

- MMR 08/09/2016

- MenB 06/28/2016

- HPV 01/23/2016

2 02/05/2017 03/05/2017

HPV 01/08/2017

3 06/08/2017 07/08/2017

HPV 07/08/2017

09/30/2017

HPV

HPV 03/28/2017

1 06/02/2014 06/02/2016 HPV 08/01/2016

2 08/29/2016 09/26/2016 HPV 08/01/2016

3 01/01/2017 02/02/2017

HPV 08/29/2016

HPV 01/23/2017

2 03/30/2017 03/30/2017

MenB

03/02/2017

-

MenB 03/30/2017

2 06/01/2021 06/01/2021

Meningococ 06/01/2021

1 02/17/2000 02/17/2000

Cholera

07/18/2017

-

Cholera

07/18/2017

Cholera

08/01/2017

Evaluation_Date_adde Date_upda Forecast_T Reason_Fo Changed_In_Version

All Valid: Recommen
Forecast ded based
Test 01/01/2013 12/06/2013 on age
Not
recommen
All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

All Valid: Recommen
Forecast ded based
Test 01/01/2013 01/01/2013 on age
Not

recommen

All Valid: ded: Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded: Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 09/17/2015 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

No Doses ded:

Administer contraindic

ed 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 11/23/2015 ation

Not

recommen

No Doses ded:

Administer contraindic

ed 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

No Doses recommen Administer ded:

ed 01/01/2013 01/01/2013 immune

Not

No Doses recommen Administer ded: ed 01/01/2013 01/01/2013 immune

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 01/01/2013 01/01/2013 ation

Not

recommen

No Doses ded:

Administer contraindic

ed 01/01/2013 01/01/2013 ation

Not

No Doses recommen Administer ded: ed 06/23/2015 06/23/2015 immune

Not

No Doses recommen
Administer ded:
ed 06/23/2015 06/23/2015 immune

Not

No Doses recommen
Administer ded:
ed 06/23/2015 06/23/2015 immune

All Valid: Recommen Forecast ded based Test 06/23/2015 06/23/2015 on interval

All Valid: Recommen Forecast ded based Test 06/23/2015 06/23/2015 on interval

Not

recommen

No Doses ded:

Administer contraindic

ed 06/23/2015 06/23/2015 ation

Not

recommen

No Doses ded:

Administer contraindic

ed 06/23/2015 06/23/2015 ation

Not

recommen

No Doses ded:

Administer contraindic ed 06/23/2015 06/23/2015 ation

Updated to reflect that if a dose of the MMR vaccine has been given to a patient born before 1957, that the patient

IS

considered

All Valid: Recommen immune.

Forecast ded based

Test 06/23/2015 04/25/2017 on interval 3.1

Updated to display accurate forecasting date based

on ACIP

recommen

3.1

Recommen
No Doses ded based

Administer on

ed 08/01/2016 03/14/2017 Condition dations

Recommen

All Valid: ded based

Forecast

Test 08/01/2016 08/01/2016 Condition

Recommen

All Valid: ded based

Forecast on

Updated Past Due date

Recommen

No Doses ded based

Administer on

ed 08/01/2016 04/25/2017 Condition 3.1

Recommen

All Valid: ded based

Forecast on

Test 08/01/2016 08/01/2016 Condition

Updated to reflect the recommen ded interval of 6 months for dose #3.

Recommen

All Valid: ded based

Forecast on

Test 08/01/2016 08/23/2017 Condition 3.1

Recommen

All Valid: ded based Forecast on

No Doses ded based

Administer on

ed 08/09/2016 08/09/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/09/2016 08/09/2016 Condition

Added Past due date

Recommen

All Valid: ded based

Forecast or

Test 08/09/2016 03/16/2017 Condition 3.1

All Valid: ded based

Forecast on

Test 08/09/2016 08/09/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/09/2016 08/09/2016 Condition

Recommen

No Doses ded based

Administer or

ed 08/22/2016 08/22/2016 Condition

All Valid: ded based

Forecast on

Test 08/22/2016 08/22/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/22/2016 08/22/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/22/2016 08/22/2016 Condition

Updated forecast date to reflect indication

Recommen

No Doses ded based Administer on

age start date

ed

08/26/2016 03/16/2017 Condition 3.1

Recommen All Valid: ded based Forecast on

Test 08/26/2016 08/26/2016 Condition

Recommen All Valid: ded based Forecast on Test 08/26/2016 08/26/2016 Condition

> Updated forecast date to reflect accurate dose four forecast.

Recommen All Valid: ded based

Forecast on

08/26/2016 03/16/2017 Condition 3.1 Test

Updated to display accurate forecasting date based on ACIP recommen dations

Recommen

All Valid: ded based Forecast on

Test 08/26/2016 03/14/2016 Condition 3.1

Updated to display accurate forecasting date based on ACIP recommen dations

Recommen

No Doses ded based Administer on

ed

08/11/2016 03/14/2017 Condition 3.1

Recommen

All Valid: ded based

Forecast on

All Valid: ded based

Forecast on

Test 08/11/2016 08/11/2016 Condition

Recommen

All Valid: ded based

Forecast

Test 08/25/2016 08/25/2016 Condition

All Valid: ded based

Forecast on

Test 08/25/2016 08/25/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/25/2016 08/25/2016 Condition

All Valid: ded based

Forecast on

Test 08/11/2016 08/11/2016 Condition

Recommen

All Valid: ded based

Forecast on

Updated forecast date to match indication age for first dose which is at 15 mos

Recommen

No Doses ded based

Administer on

ed 08/15/2016 03/16/2017 Condition 3.1

Recommen

All Valid: ded based

Forecast on

Test 08/15/2016 08/15/2016 Condition

Updated

forecast date to match indication age for first dose which

Recommen is at 15 mos

No Doses ded based

Administer on

ed 08/15/2016 03/16/2017 Condition 3.1

Recommen

All Valid: ded based

Forecast or

Updated forecast date to match indication age for first dose which is at 15 mos

No Doses ded based Administer on

ed 08/23/2016 03/16/2017 Condition 3.1

Recommen
No Doses ded based
Administer on

ed 08/23/2016 08/23/2016 Condition

Updated forecst date to match indication age for first

dose at age

Recommen

No Doses ded based 6 weeks.

Administer on

ed 08/15/2016 04/25/2017 Condition 3.1

Recommen

All Valid: ded based

Forecast on

All Valid: ded based

Forecast on

Test 08/15/2016 08/15/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/15/2016 08/15/2016 Condition

Added Vaccine Group and forecast date

Recommen

No Doses ded based

Administer

ed 08/22/2016 03/16/2017 Condition 3.1

All Valid: ded based

Forecast on

Test 08/22/2016 08/22/2016 Condition

Recommen

All Valid: ded based

Forecast o

Test 08/25/2016 08/25/2016 Condition

Recommen

All Valid: ded based

Forecast

Test 08/25/2016 08/25/2016 Condition

New HPV 2 dose recommen dation and added Past Due date.

Recommen

No Doses ded based Administer on

ed 08/15/2016 04/25/2017 Condition 3.1

New HPV 2 dose recommen dation

Recommen

All Valid: ded based Forecast on

Test 08/15/2016 01/09/2017 Condition

3.1

New HPV 2 dose recommen dation

Recommen

All Valid: ded based

Forecast on

Test 08/16/2016 01/01/2017 Condition 3.1

New HPV 2 dose recommen dation

Recommen

No Doses ded based Administer on

Administer on the form of the form

ed 08/16/2016 01/01/2017 Condition 3.1

New HPV 2 dose recommen dation

Recommen

All Valid: ded based

Forecast on

Test 08/16/2016 01/09/2017 Condition 3.1

Update test case with observation al code 148.

Recommen

All Valid: ded based

Forecast on

Test 08/17/2016 04/25/2017 Condition 3.1

Updated Earliest, Recommen ded, and

Recommen dates

All Valid: ded based

Forecast on

Test 08/17/2016 04/27/2016 Condition 3.1

Updated Earliest, Recommen ded, and Past due

Recommen

All Valid: ded based

Forecast on

Test 08/17/2016 04/27/2017 Condition 3.1

Updated Earliest, Recommen ded, and past due date based on HPV Recommen dations

Recommen

All Valid: ded based

Forecast on

Test 08/18/2016 04/27/2017 Condition 3.1

Recommen

All Valid: ded based

Forecast on

Recommen ded based

Administer on

No Doses

ed 08/23/2016 08/23/2016 Condition

All Valid: ded based

Forecast on

Test 08/23/2016 08/23/2016 Condition

All Valid: ded based

Forecast on
Test 08/23/2016 08/23/2016 Condition

Updated Vaccine Group to MMR. Added Past due date.

Recommen

No Doses ded based

Administer on

ed 08/18/2016 04/27/2016 Condition 3.1

All Valid: ded based

Forecast on

Test 08/18/2016 08/18/2016 Condition

Recommen

All Valid: ded based

Forecast on

All Valid: ded based

Forecast or

All Valid: ded based

Forecast or

Test 08/18/2016 08/18/2016 Condition

Recommen

No Doses ded based

Administer on

ed 08/18/2016 08/18/2016 Condition

Recommen

All Valid: ded based

Forecast

All Valid: ded based

Forecast on

Test 08/18/2016 08/18/2016 Condition

Recommen

No Doses ded based

Administer or

ed 08/30/2016 08/30/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/30/2016 08/30/2016 Condition

All Valid: ded based

Forecast on

Test 08/30/2016 08/30/2016 Condition

Recommen

No Doses ded based

Administer on

ed 09/07/2016 09/07/2016 Condition

Recommen

All Valid: ded based

Forecast or

Test 09/07/2016 09/07/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 09/07/2016 09/07/2016 Condition

All Valid: ded based

Forecast on

Test 09/07/2016 09/07/2016 Condition

Recommen

No Doses ded based

Administer on

ed 09/07/2016 09/07/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 09/07/2016 09/07/2016 Condition

All Valid: ded based

Forecast on

Test 09/07/2016 09/07/2016 Condition

Recommen

All Valid: ded based

Forecast or

Test 09/08/2016 09/08/2016 Condition

All Valid: ded based

Forecast on

Test 09/08/2016 09/08/2016 Condition

Recommen

All Valid: ded based

Forecast

Test 09/08/2016 09/08/2016 Condition

All Valid: ded based

Forecast on

Test 09/08/2016 09/08/2016 Condition

Recommen

No Doses ded based

Administer on

ed 09/08/2016 09/08/2016 Condition

All Valid: ded based

Forecast on

Test 09/09/2016 09/09/2016 Condition

Recommen

All Valid: ded based

Forecast

Test 09/09/2016 09/09/2016 Condition

No Doses ded based

Administer on

ed 09/09/2016 09/09/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 09/09/2016 09/09/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 09/09/2016 09/09/2016 Condition

All Valid: ded based

Forecast on

Test 09/09/2016 09/09/2016 Condition

Recommen

All Valid: ded based

Forecast or

Test 09/09/2016 09/09/2016 Condition

All Valid: ded based

Forecast on

Test 09/09/2016 09/09/2016 Condition

Recommen

All Valid: ded based

Forecast or

Test 09/09/2016 09/09/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 09/09/2016 09/09/2016 Condition

All Valid: ded based

Forecast on Test

09/09/2016 09/09/2016 Condition

Updated

Recommen

No Doses ded based

Administer

08/30/2016 03/16/2017 Condition ed 3.1

Recommen

All Valid: ded based

Forecast on

08/30/2016 08/30/2016 Condition Test

Not

recommen

No Doses ded:

Administer contraindic ed 08/30/2016 08/30/2016 ation

All Valid: ded based

Forecast on

Test 08/30/2016 08/30/2016 Condition

Recommen

No Doses ded based

Administer on

ed 08/23/2016 08/23/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/23/2016 08/23/2016 Condition

All Valid: ded based

Forecast on

Test 08/19/2016 08/19/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/19/2016 08/19/2016 Condition

Recommen

No Doses ded based

Administer on

ed 08/19/2016 08/19/2016 Condition

All Valid: ded based

Forecast on

Test 08/19/2016 08/19/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/19/2016 08/19/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/19/2016 08/19/2016 Condition

All Valid: ded based

Forecast or

Test 08/26/2016 08/26/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/26/216 08/26/2016 Condition

Recommen

No Doses ded based

Administer on

ed 08/26/2016 08/26/2016 Condition

All Valid: ded based

Forecast on

Test 08/26/2016 08/26/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/26/2016 08/26/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/29/2016 08/29/2016 Condition

All Valid: ded based

Forecast on

Test 08/29/2016 08/29/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/29/2016 08/29/2016 Condition

Recommen

No Doses ded based

Administer on

ed 08/19/2016 08/19/2016 Condition

All Valid: ded based

Forecast on

Test 08/19/2016 08/19/2016 Condition

All Valid: ded based

Forecast on

Test 08/19/2016 08/19/2016 Condition

Recommen ded based

Administer on

No Doses

ed 08/29/2016 08/29/2016 Condition

All Valid: ded based

Forecast on

Test 08/29/2016 08/29/2016 Condition

Recommen ded based

Administer on

No Doses

ed 08/22/2016 08/22/2016 Condition

All Valid: ded based

Forecast on O8/22/2016 08/22/2016 Condition

Updated to reflect the correct forecasting date.

Recommen

All Valid: ded based Forecast on

Orecast

Test 08/30/2016 08/23/2017 Condition 3.1

Updated to

Recommen add Past
No Doses ded based Due date

Administer on

ed 08/30/2016 08/23/2017 Condition 3.1

No Doses ded based

Administer on

ed 09/01/2016 09/01/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 09/01/2016 09/01/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 09/01/2016 09/01/2016 Condition

Update to reflect the correct forecasting date.

Recommen

All Valid: ded based

Forecast on

Test 09/02/2016 08/23/2017 Condition 3.1

Recommen

All Valid: ded based

Forecast on

Test 09/02/2016 09/02/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 09/02/2016 09/02/2016 Condition

All Valid: ded based

Forecast on

Test 09/02/2016 09/02/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 09/02/2016 09/02/2016 Condition

Recommen

All Valid: ded based

Forecast

Test 09/06/2016 09/06/2016 Condition

Recommen
All Valid: ded based
Forecast on
Test 09/06/2016 09/06/2016 Condition

Updated to reflect an additional contraindic ation/obser vation.

3.1

Not

recommen

All Valid: ded: Forecast contraindic

Test 08/23/2016 03/16/2017 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 08/23/2016 08/23/2016 ation

No Doses ded based

Administer or

ed 08/25/2016 08/25/2016 Condition

Recommen

All Valid: ded based

Forecast or

Test 08/25/2016 08/25/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/25/2016 08/25/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/25/2016 08/25/2016 Condition

Not

recommen

All Valid: ded:

Forecast contraindic

Test 08/26/2016 08/26/2016 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 08/26/2016 08/26/2016 ation

Updated to reflect an additional contraindic

ation/obser vation.

Recommen

All Valid: ded based

Forecast on

Test 08/22/2016 03/16/2017 Condition 3.1

Recommen ded based

Forecast on

All Valid:

Test 08/29/2016 08/29/2016 Condition

Updated to reflect an additional contraindic ation/obser vation.

Recommen

All Valid: ded based

Forecast

Test 08/22/2016 03/16/2017 Condition 3.1

Recommen

No Doses ded based

Administer on

ed 08/22/2016 08/22/2016 Condition

Updated to reflect correct Past Due date

Recommen

No Doses ded based

Administer on

ed 08/26/2016 08/23/2017 Condition 3.1

Recommen

No Doses ded based

Administer on

ed 08/30/2016 08/30/2016 Condition

Recommen

All Valid: ded based

Forecast on

Test 08/30/2016 08/30/2016 Condition

Recommen

All Valid: ded based

Forecast

Test 08/30/2016 08/30/2016 Condition

All Valid: ded based

Forecast on

Test 08/30/2016 08/30/2016 Condition

Recommen

No Doses ded based

Administer on

ed 08/02/2016 08/02/2016 Condition

Not

recommen

All Valid: ded:

Forecast contraindic

Test 08/26/2016 08/26/2016 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 08/26/2016 08/26/2016 ation

Not

recommen

No Doses ded:

Administer contraindic ed 08/09/2016 08/09/2016 ation

Not

recommen

All Valid: ded:

Forecast contraindic

Test 09/19/2016 09/19/2016 ation

Recommen

All Valid: ded based

Forecast on

Test 01/09/2017 01/09/2017 Condition

Recommen

No Doses ded based

Administer on

ed 01/10/2017 01/10/2017 Condition

All Valid: ded based

Forecast on

Test 02/02/2017 02/02/2017 Condition

Recommen

All Valid: ded based

Forecast

Test 02/02/2017 02/02/2017 Condition

Recommen

All Valid: ded based

Forecast

Test 02/02/2017 02/02/2017 Condition

All Valid: ded based

Forecast on

Test 02/02/2017 02/02/2017 Condition

Recommen

No Doses ded based

Administer on

ed 02/02/2017 02/02/2017 Condition

Recommen

All Valid: ded based

Forecast or

Test 02/02/2017 02/02/2017 Condition

All Valid: ded based

Forecast on

Test 02/02/2017 02/02/2017 Condition

Recommen

All Valid: ded based

Forecast on

Test 02/02/2017 02/02/2017 Condition

Recommen

No Doses ded based

Administer on

ed 03/20/2017 03/20/2017 Condition

All Valid: ded based

Forecast or

Test 03/20/2017 03/20/2017 Condition

Recommen
All Valid: ded based
Forecast on

Test 03/20/2017 03/20/2017 Condition

Recommen

All Valid: ded based

Forecast on

Test 03/20/2017 03/20/2017 Condition

No Doses ded based

Administer on

ed 07/18/2017 07/18/2017 Condition

Recommen

All Valid: ded based

Forecast on

Test 07/18/2017 07/18/2017 Condition

Not

recommen

No Doses ded:

Administer contraindic ed 08/22/2017 08/22/2017 ation